INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
批准号:
6105301
负责人:
SHARON L REED
金额:
$14.5万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-04-01 至 2000-03-31
关键词:
Entamoeba histolytica RNase protection assay SCID mouse SDS polyacrylamide gel electrophoresis affinity chromatography amebiasis cysteine endopeptidases cytokine enzyme activity enzyme linked immunosorbent assay fluorescence microscopy high performance liquid chromatography host organism interaction human tissue immunoglobulin A immunoglobulin G intracellular parasitism mucosal immunity neutrophil parasitic gastrointestinal disorder polymerase chain reaction protein purification protozoal infection southern blotting superoxide dismutase western blottings
中文摘要
溶组织内阿米巴是寄生虫致死的第三大原因
疾病,然而,决定一种菌株引起
人们对侵袭性阿米巴病知之甚少。研究的重点是
与肠粘膜相互作用的差异
潜在入侵性组织裂殖吸虫和共生原生动物E.
DISPAR,应提供对
肠子。才能成功入侵。溶组织棘球绦虫滋养体必须
绕过许多针对SIgA的免疫和非免疫宿主防御
活化的中性粒细胞及其氧化的杀菌活性
产品。我们将评估组织裂解杆菌和裂解乳杆菌之间的相互作用。
通过以下方式消除宿主粘膜防御:
目的1.评价SIgA在预防阿米巴感染中的作用
免疫SIgA对滋养体结合的影响及其对免疫功能的影响
诱导炎性细胞因子反应,裂解SIgA。
溶组型半胱氨酸蛋白酶的表达及特异性SIgA对其影响
侵袭人体肠道异种移植物。
目的2.比较溶组织乳杆菌和致病乳杆菌对细菌的敏感性。
检测中性粒细胞及其氧化能力的氧化攻击
杀灭溶组织性肠杆菌和散发性肠杆菌的产品,比较抗氧化剂
溶组织肠杆菌、迪帕尔肠杆菌和兰氏革兰氏菌的活性测定
SIgA或Ig G阻断抗氧化活性的能力,并评价
抗氧化剂基因的调控。
目的3.评价阻断抗氧化剂对阿米巴的影响
29kD抗氧化剂和超氧化物的消融表达侵袭
利用反义RNA表达溶组埃希氏菌中的超氧化物歧化酶
溶组织乳杆菌的抗氧化性基因,并检测其重要性。
抗氧化剂对人异种肠道移植瘤侵袭的影响。
通过提供关于寄生虫和宿主因素的重要新见解,
确定感染溶组织性肠杆菌和E。
迪帕尔,这些研究将增加我们对基本宿主的了解
肠道防御系统。
英文摘要
Entamoeba histolytica is the third leading cause of death from parasitic
disease, yet the factors which determine the ability of a strain to cause
invasive amebiasis are poorly understood. Studies focused on the
differences between the interactions with the intestinal mucosal of
potentially invasive E. histolytica and the commensal protozoan, E.
dispar, should provide important insights into basic host defenses in the
bowel. For successful invasion. E. histolytica trophozoites must
circumvent a number of immune and non-immune host defenses against sIgA
and the microbicidal activity of activated neutrophils and their oxidative
products. We will evaluate the interactions of E. histolytica and E.
dispar with host mucosal defenses by:
Aim 1. Evaluate the role of sIgA in protection against amebic infection by
evaluating the effect of immune sIgA on trophozoite binding and on the
induction of an inflammatory cytokine response, cleavage of sIgA by the E.
histolytica cysteine proteinase, and the effect of specific sIgA on
invasion in human intestinal xenografts.
Aim 2. Compare the susceptibility of E. histolytica and E. dispar to
oxidative attack by testing the ability of neutrophils and their oxidative
products to kill E. histolytica and E. dispar, comparing the antioxidant
activity of E. histolytica, E. dispar and G. lamblia, determining the
ability of sIgA or IgG to block antioxidant activity, and evaluating the
regulation of the antioxidant gene.
Aim 3. Evaluate the effect of blocking antioxidant activity on amebic
invasion by ablating expression of the 29 kD antioxidant and superoxide
dismutase in E. histolytica by antisense RNAs, transfecting E. dispar with
the antioxidant gene for E. histolytica, and testing the importance of
antioxidant activity on invasion of human intestinal xenografts.
By providing important new insights into parasite and host factors which
determine the outcome of infection invade with E. histolytica and E.
dispar, these studies will increase our knowledge of the basic host
defenses in the bowel.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase IIa Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa
-
批准号:9477452
-
项目类别:
-
资助金额:$60.04万
-
财政年份:2015
-
负责人:SHARON L REED
-
依托单位:
Phase IIa Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa
-
批准号:9063467
-
项目类别:
-
资助金额:$60.71万
-
财政年份:2015
-
负责人:SHARON L REED
-
依托单位:
Planning Grant for the Efficacy of Auranofin for the Treatment of Amebiasis
-
批准号:8264457
-
项目类别:
-
资助金额:$22.6万
-
财政年份:2012
-
负责人:SHARON L REED
-
依托单位:
Novel Therapeutics for Class B Protozoa
-
批准号:8065366
-
项目类别:
-
资助金额:$136.68万
-
财政年份:2008
-
负责人:SHARON L REED
-
依托单位:
Novel Therapeutics for Class B Protozoa
-
批准号:7452689
-
项目类别:
-
资助金额:$130.0万
-
财政年份:2008
-
负责人:SHARON L REED
-
依托单位:
Novel Therapeutics for Class B Protozoa
-
批准号:7622064
-
项目类别:
-
资助金额:$137.19万
-
财政年份:2008
-
负责人:SHARON L REED
-
依托单位:
Novel Therapeutics for Class B Protozoa
-
批准号:7804552
-
项目类别:
-
资助金额:$138.06万
-
财政年份:2008
-
负责人:SHARON L REED
-
依托单位:
Novel Therapeutics for Class B Protozoa
-
批准号:8260231
-
项目类别:
-
资助金额:$137.16万
-
财政年份:2008
-
负责人:SHARON L REED
-
依托单位:
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
-
批准号:6579405
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2002
-
负责人:SHARON L REED
-
依托单位:
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
-
批准号:6580369
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2002
-
负责人:SHARON L REED
-
依托单位:
Genetic Manipulation of Entamoeba Virulence
-
批准号:6534324
-
项目类别:
-
资助金额:$22.61万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
-
批准号:6450321
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
Genetic Manipulation of Entamoeba Virulence
-
批准号:6908202
-
项目类别:
-
资助金额:$30.4万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
-
批准号:6576197
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
Genetic Manipulation of Entamoeba Virulence
-
批准号:6735687
-
项目类别:
-
资助金额:$30.4万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
Genetic Manipulation of Entamoeba Virulence
-
批准号:6325559
-
项目类别:
-
资助金额:$26.59万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
-
批准号:6438193
-
项目类别:
-
资助金额:$22.18万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
Genetic Manipulation of Entamoeba Virulence
-
批准号:6637846
-
项目类别:
-
资助金额:$26.6万
-
财政年份:2001
-
负责人:SHARON L REED
-
依托单位:
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
-
批准号:6395852
-
项目类别:
-
资助金额:$14.5万
-
财政年份:2000
-
负责人:SHARON L REED
-
依托单位:
INTERACTIONS OF E HISTOLYTICA WITH HOST MUCOSAL DEFENSES
-
批准号:6296429
-
项目类别:
-
资助金额:$14.5万
-
财政年份:1999
-
负责人:SHARON L REED
-
依托单位:
海外基金